Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6723-6729

  Kujan, Omar ^a   Oliver, Richard ^a   Roz, Luca ^d   Sozzi, Gabriella ^d   Ribeiro, Noel ^b   Woodwards, Robert ^b   Thakker, Nalin ^a,c   Sloan, Philip ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DYSPLASIA; ENZYME INACTIVATION; ENZYME LOCALIZATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; SURVIVAL ANALYSIS;

EID: 33845326100     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1475     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. La Vecchia C, Lucchini F, Negri E, Levi F. Trends in oral cancer mortality in Europe. Oral Oncol 2004;40:433-9.
3. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J. Cancer of the base of the tongue: past and future. Head Neck 1999;21:751-9.
4. Wu CL, Sloan P, Read AP, Harris R, Thakker N. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 1994;54:6484-8.
5. Roz L, Wu CL, Porter S, et al. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 1996;56:1228-31.
6. Campiglio M, Blanchi F, Andriani F, et al. Diadenosines as FHIT-ness instructors. J Cell Physiol 2006;208:274-81.
7. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 2002;62:6447-50.
8. Iliopoulos D, Guler G, Han SY, et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 2006;232:27-36.
9. Lee JI, Soria JC, Hassan K, et al. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res 2001;61:837-41.
10. Guerin LA, Hoffman HT, Zimmerman MB, Robinson RA. Decreased fragile histidine triad gene protein expression is associated with worse prognosis in oral squamous carcinoma. Arch Pathol Lab Med 2006;130:158-64.
11. Tai SK, Lee JI, Ang KK, et al. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res 2004;10:5554-7.
12. Barnes L, Eveson J, Reichart P, Sidransky D. World Health Organization classification of tumors. Pathology and genetics of tumors of the head and neck. Lyon: IARC Press; 2005. p. 177-80.
13. Sobin LH, Wittekind C, International Union Against Cancer. TIMM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 22-6.
14. Ishii H, Ozawa K, Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol 2003;3:291-6.
15. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002;3:748-54.
16. Hsieh CL, Jones PA. Meddling with methylation. Nat Cell Biol 2003;5:502-4.
17. Lee EJ, Lee BB, Kim JW, et al. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer 2006;42:972-80.
18. van Heerden WF, Swart TJ, Robson B, et al. FHIT RNA and protein expression in oral squamous cell carcinomas. Anticancer Res 2001;21:2425-8.
19. van Heerden WF, Swart TJ, van Heerden MB, Pekarsky Y, Sutherland R, Huebner K. Fhit protein expression in oral epithelium: immunohistochemical evaluation of three antisera. Anticancer Res 2001;21:2419-23.
20. Mineta H, Miura K, Takebayashi S, et al. Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol 2003;39:56-63.
21. Paradiso A, Ranieri G, Stea B, et al. Altered p16INK4a and Fhit expression in carcinogenesis and progression of human oral cancer. Int J Oncol 2004;24:249-55.
22. Chang KW, Kao SY, Tzeng RJ, et al. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J Pathol 2002;196:300-6.
23. Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res 2006;4:93-9.
24. Holschneider CH, Baldwin RL, Tumber K, Aoyama C, Karlan BY. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer. Clin Cancer Res 2005;11:5756-63.
25. Huang LW, Chao SL, Chen TJ. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol 2003;90:331-7.
26. Yang Q, Yoshimura G, Suzuma T, et al. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 2001;7:3869-73.
27. Golebiowski F, Kowara R, Pawelczyk T. Distribution of Fhit protein in rat tissues and its intracellular localization. Mol Cell Biochem 2001;226:49-55.
28. Zhao P, Hou N, Lu Y. Fhit protein is preferentially expressed in the nucleus of monocyte-derived cells and its possible biological significance. Histol Histopathol 2006;21:915-23.
29. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
30. Shimada Y, Sato F, Watanabe G, et al. Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 2000;89:5-11.
31. Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000;60:18-21.
32. Gatalica Z, Lele SM, Rampy BA, Morris BA. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000;88:1378-83.
33. Birrer MJ, Hendricks D, Farley J, et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999;59:5270-4.
34. Huebner K, Druck T, Siprashvili Z, Croce CM, Kovatich A, McCue PA. The role of deletions at the FRA3B/FHIT locus in carcinogenesis. Recent Results Cancer Res 1998;54:200-15.
35. Dumon KR, Ishii H, Fong LY, et al. FHIT ene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A 2001;98:3346-51.
36. el-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 1995;55:2656-9.
37. Virgilio L, Shuster M, Gollin SM, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A 1996;93:9770-5.
38. Kannan K, Munirajan AK, Bhuvarahamurthy V, et al. FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol 2000;36:189-93.
39. Tanimoto K, Hayashi S, Tsuchiya E, et al. Abnormalities of the FHITgene in human oral carcinogenesis. Br J Cancer 2000;82:838-43.
40. Kitamura A, Yashima K, Okamoto E, et al. Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology 2001;61:205-11.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
42. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
43. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
44. Lo Muzio L, Pannone G, Leonardi R, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003;82:923-8.
45. Kujan O, Desai M, Sargent A, Bailey A, Turner A, Sloan P. Potential applications of oral brush cytology with liquid-based technology: results from a cohort of normal oral mucosa. Oral Oncol 2006;42:810-8.
46. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 2002;99:3615-20.
47. Ishii H, Vecchione A, Fong LY, et al. Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses. Curr Gene Ther 2004;4:53-63.
48. Pichiorri F, Trapasso F, Palumbo T, et al. Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 2006;12:3494-501.